IPF Respiratory Symptoms Management - Current Evidence

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2022 Aug 15

PMID 35966835

Authors

Piotr Janowiak

Amelia Szymanowska-Narloch

Alicja Sieminska

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic disease of the lungs which is characterized by heavy symptom burden, especially in the last year of life. Despite recently established anti-fibrotic treatment IPF prognosis is one of the worst among interstitial lung diseases. In this review available evidence regarding pharmacological and non-pharmacological management of the main IPF symptoms, dyspnea and cough, is presented.

Citing Articles

Pulmonary fibroblast-specific delivery of siRNA exploiting exosomes-based nanoscaffolds for IPF treatment.

Lu H, Liu X, Zhang M, Bera H, Xu W, Jiang H Asian J Pharm Sci. 2024; 19(4):100929.

PMID: 39258001 PMC: 11385781. DOI: 10.1016/j.ajps.2024.100929.

Lung cell transplantation for pulmonary fibrosis.

Milman Krentsis I, Zheng Y, Rosen C, Shin S, Blagdon C, Shoshan E Sci Adv. 2024; 10(34):eadk2524.

PMID: 39178253 PMC: 11343030. DOI: 10.1126/sciadv.adk2524.

Respiratory diseases and gut microbiota: relevance, pathogenesis, and treatment.

Sun M, Lu F, Yu D, Wang Y, Chen P, Liu S Front Microbiol. 2024; 15:1358597.

PMID: 39081882 PMC: 11286581. DOI: 10.3389/fmicb.2024.1358597.

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant.

Reccardini N, Chernovsky M, Salton F, Confalonieri P, Mondini L, Barbieri M Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065780 PMC: 11280355. DOI: 10.3390/ph17070930.

Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives.

Vancheri C, Sciacca E, Muscato G, Spicuzza L, Fruciano M, Gili E Multidiscip Respir Med. 2024; 19.

PMID: 38869027 PMC: 11186439. DOI: 10.5826/mrm.2024.982.

References

Birring S, Wijsenbeek M, Agrawal S, van den Berg J, Stone H, Maher T . A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017; 5(10):806-815. DOI: 10.1016/S2213-2600(17)30310-7. View

Mahler D . Opioids for refractory dyspnea. Expert Rev Respir Med. 2013; 7(2):123-34. DOI: 10.1586/ers.13.5. View

Rajala K, Lehto J, Saarinen M, Sutinen E, Saarto T, Myllarniemi M . End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliat Care. 2016; 15(1):85. PMC: 5059981. DOI: 10.1186/s12904-016-0158-8. View

Keyser R, Woolstenhulme J, Chin L, Nathan S, Weir N, Connors G . Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. J Cardiopulm Rehabil Prev. 2014; 35(1):47-55. PMC: 4276491. DOI: 10.1097/HCR.0000000000000083. View

Young I, Daviskas E, Keena V . Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989; 44(5):387-90. PMC: 461838. DOI: 10.1136/thx.44.5.387. View

Ryan N, Birring S, Gibson P . Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 380(9853):1583-9. DOI: 10.1016/S0140-6736(12)60776-4. View

Holland A, Hill C, Glaspole I, Goh N, McDonald C . Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2011; 106(3):429-35. DOI: 10.1016/j.rmed.2011.11.014. View

Vainshelboim B . Exercise training in idiopathic pulmonary fibrosis: is it of benefit?. Breathe (Sheff). 2016; 12(2):130-8. PMC: 4933618. DOI: 10.1183/20734735.006916. View

ODonnell D, Milne K, James M, de Torres J, Neder J . Dyspnea in COPD: New Mechanistic Insights and Management Implications. Adv Ther. 2019; 37(1):41-60. PMC: 6979461. DOI: 10.1007/s12325-019-01128-9. View

10.

Leung R, Hill P, Burdon J . Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996; 51(6):596-600. PMC: 1090489. DOI: 10.1136/thx.51.6.596. View

11.

Schaeffer M, Ryerson C, Ramsook A, Molgat-Seon Y, Wilkie S, Dhillon S . Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. Eur Respir J. 2017; 49(5). DOI: 10.1183/13993003.02494-2016. View

12.

Sridhar G, Clemens R, Zintel T, Gallagher C, Marciniuk D . Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med. 1995; 152(6 Pt 1):1940-5. DOI: 10.1164/ajrccm.152.6.8520759. View

13.

Birring S, Kavanagh J, Irwin R, Keogh K, Lim K, Ryu J . Treatment of Interstitial Lung Disease Associated Cough: CHEST Guideline and Expert Panel Report. Chest. 2018; 154(4):904-917. DOI: 10.1016/j.chest.2018.06.038. View

14.

Storgaard L, Weinreich U, Laursen B . COPD Patients' Experience of Long-Term Domestic Oxygen-Enriched Nasal High Flow Treatment: A Qualitative Study. COPD. 2020; 17(2):175-183. DOI: 10.1080/15412555.2020.1736998. View

15.

Goda K, Kenzaka T, Kuriyama K, Hoshijima M, Akita H . End-of-life home care of an interstitial pneumonia patient supported by high-flow nasal cannula therapy: A case report. World J Clin Cases. 2020; 8(20):4853-4857. PMC: 7642529. DOI: 10.12998/wjcc.v8.i20.4853. View

16.

Piotrowski W, Bestry I, Bialas A, Boros P, Grzanka P, Jassem E . Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis. Adv Respir Med. 2020; 88(1):41-93. DOI: 10.5603/ARM.2020.0081. View

17.

Morice A, Menon M, Mulrennan S, Everett C, Wright C, Jackson J . Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2006; 175(4):312-5. DOI: 10.1164/rccm.200607-892OC. View

18.

Schaeffer M, Ryerson C, Ramsook A, Molgat-Seon Y, Wilkie S, Dhillon S . Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease. Eur Respir J. 2018; 51(1). DOI: 10.1183/13993003.01726-2017. View

19.

Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, Rapti A . Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. Lung. 2011; 189(5):391-9. DOI: 10.1007/s00408-011-9304-5. View

20.

Plantier L, Cazes A, Dinh-Xuan A, Bancal C, Marchand-Adam S, Crestani B . Physiology of the lung in idiopathic pulmonary fibrosis. Eur Respir Rev. 2018; 27(147). PMC: 9489199. DOI: 10.1183/16000617.0062-2017. View